Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
MISSISSAUGA, Ontario, May 3, 2017 /PRNewswire/ --Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) (TSX:ARZ) ("Aralez" or the "Company") today announced the results of the matters voted upon at the Company's 2017 annual and special meeting (the "Meeting") of the shareholders of the Company (the "Shareholders") held earlier today, which included the election of directors, as described below.
The total number of common shares of the Company ("Common Shares") represented by Shareholders present in person or represented by proxy at the Meeting was an aggregate of 51,367,656, representing 78.20% of the Company's issued and outstanding Common Shares as of the record date for the Meeting.
According to proxies received and a vote by ballot, the voting results in respect of each of the following eight director nominees, all of whom previously served as directors of the Company, were as follows:
Nominee
Number of Shares
Percentage of Votes Cast
(approximate)
Votes For:
Votes Withheld:
Votes For:
Votes Withheld:
Arthur S. Kirsch (Chairperson)
22,485,659
9,875,061
69.48%
30.52%
Adrian Adams
28,920,565
3,440,155
89.37%
10.63%
Jason M. Aryeh
26,164,091
6,196,629
80.85%
19.15%
Neal F. Fowler
28,935,289
3,425,431
89.41%
10.59%
Rob Harris
22,469,931
9,890,789
69.44%
30.56%
Kenneth B. Lee, Jr.
28,922,730
3,437,990
89.38%
10.62%
Seth A. Rudnick, M.D.
22,527,866
9,832,854
69.61%
30.39%
F. Martin Thrasher
28,932,500
3,428,220
89.41%
10.59%
Each of the other matters put forward before Shareholders for consideration and approval at the Meeting, as described in the Company's proxy statement dated March 23, 2017, was duly approved by the requisite number of votes, with Shareholders voting in favour of holding future non-binding, advisory say-on-pay votes to approve the Company's approach to the compensation of its named executive officers on an annual basis.
Final voting results of all other matters voted on at the Meeting will be made available on EDGAR at www.sec.gov and SEDAR at www.sedar.com.
About Aralez Pharmaceuticals Inc. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) (TSX:ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Mississauga, Ontario, Canada, its U.S. Headquarters is in Princeton, New Jersey and its Ireland Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.
